Presented at the 66th Annual Meeting of the Canadian Society of Otolaryngology–Head & Neck Surgery, Toronto, Ontario, Canada, May 20–22, 2012.
Corticosteroids in peritonsillar abscess treatment: A blinded placebo-controlled clinical trial
Article first published online: 9 JUL 2013
© 2013 The American Laryngological, Rhinological and Otological Society, Inc.
Volume 124, Issue 1, pages 97–103, January 2014
How to Cite
Chau, J. K. M., Seikaly, H. R., Harris, J. R., Villa-Roel, C., Brick, C. and Rowe, B. H. (2014), Corticosteroids in peritonsillar abscess treatment: A blinded placebo-controlled clinical trial. The Laryngoscope, 124: 97–103. doi: 10.1002/lary.24283
The authors have no other funding, financial relationships, or conflicts of interest to disclose.
Funding support for this project was generously provided by the University Hospital Foundation and the Department of Emergency Medicine Research Group at the University of Alberta (c.v.-r., c.b.). c.v.-r. is supported by the Canadian Institutes of Health Research (CIHR) in partnership with the Knowledge Translation branch. b.h.r. is supported by the CIHR as Tier I Canada Research Chair in Evidence-Based Emergency Medicine (Government of Canada).
- Issue published online: 20 DEC 2013
- Article first published online: 9 JUL 2013
- Accepted manuscript online: 22 JUN 2013 02:40AM EST
- Manuscript Revised: 6 JUN 2013
- Manuscript Accepted: 6 JUN 2013
- Peritonsillar abscess;
- sore throat;
- randomized controlled trial
Sore throat is a common, benign emergency department (ED) presentation; however, peritonsillar abscess (PTA) is a complication that requires aggressive management. Use of systemic corticosteroids (SCSs) in PTA is occurring without clear evidence of benefit. This study examined the efficacy and safety of SCS treatment for patients with PTA.
Randomized, double-blind, placebo-controlled trial.
A controlled trial with concealed allocation and double-blinding was conducted at two Canadian EDs. Following written informed consent, eligible patients received 48 hours of intravenous clindamycin and a single dose of the study drug (dexamethasone [DEX] or placebo [PLAC], intravenously [IV]). Follow-up occurred at 24 hours, 48 hours, and 7 days. The primary outcome was pain; other outcomes were side effects and return to normal activities/diet.
A total of 182 patients were screened for eligibility; 41 patients were enrolled (21 DEX; 20 PLAC). At 24 hours, those receiving DEX reported lower pain scores (1.4 vs. 5.1; P = .009); however, these differences disappeared by 48 hours (P = .22) and 7 days (P = .4). At 24 hours, more patients receiving DEX returned to normal activities (33% vs. 11%) and dietary intake (38% vs 25%); however, these differences were not significant and disappeared by 48 hours and 7 days. Side effects were rare and did not differ between groups (P > .05).
Combined with PTA drainage and IV antibiotics, 10 mg IV DEX resulted in less pain at 24 hours when compared to PLAC, without any serious side effects. This effect is short-lived, and further research is required on factors associated with PTA treatment success.
Level of Evidence
1b Laryngoscope, 124:97–103, 2014